CaverSTIM Implantable Neurostimulator Shows Promise in First-in-Man Study for Post-Prostatectomy Erectile Dysfunction
核心洞察
A first-in-man clinical study of the CaverSTIM (搜索) implantable cavernous nerve (搜索) neurostimulator demonstrated safety and feasibility, with 9 of 10 patients regaining potency following robot-assisted radical prostatectomy.
The device showed no device explantations, infections, or pain during stimulation, with only mild transient discomfort reported in two patients during the 6-month follow-up period.
Comphya (搜索) plans to initiate larger controlled clinical trials to further evaluate the device's safety and efficacy, while also exploring applications for other neurogenic causes of erectile dysfunction (搜索).
A groundbreaking first-in-man clinical study has demonstrated the safety and early efficacy of CaverSTIM (搜索), an implantable cavernous nerve (搜索) neurostimulator designed to restore erectile function following robot-assisted radical prostatectomy (RARP). The results, published in BJU International, show that 9 of 10 patients regained potency after receiving the device, marking a significant advancement in post-prostatectomy erectile dysfunction (搜索) treatment.
Study Design and Safety Profile
The prospective pilot study (NCT05650866) enrolled 10 men who were potent before undergoing RARP. All patients received the CaverSTIM (搜索) implant during their prostatectomy procedure and were instructed to activate the device daily during a 6-month follow-up period.
The study met its primary safety and tolerability objectives with an excellent safety profile. No device explantations, device-related infections, or pain during stimulation were reported throughout the study period. Only two patients experienced mild, transient discomfort. The implantation procedure added approximately 45 minutes to the standard RARP surgery time.
Promising Functional Outcomes
The functional results exceeded expectations, with 9 of 10 patients regaining postoperative potency. Many participants were able to resume unaided sexual intercourse, representing a substantial improvement over typical post-prostatectomy outcomes. Erectile function was assessed using validated IIEF-15 questionnaires and nocturnal RigiScan monitoring, both demonstrating recovery of erectile activity over time.
"These publications reflect a major step forward for CaverSTIM (搜索) and for Comphya (搜索)," said Pim van Wesel, CEO of Comphya. "Seeing our technology validated in a first-in-man clinical study reinforces our confidence that neuromodulation can meaningfully improve quality-of-life outcomes for men undergoing prostate cancer (搜索) surgery."
Scientific Foundation and Mechanism
Concurrent with the clinical study publication, a comprehensive scientific review in Nature Urology Review outlined the rationale for implantable neurostimulation in managing post-prostatectomy erectile dysfunction (搜索). The approach is supported by 150 years of research demonstrating erection responses following electrical stimulation.
The technology targets penile nerve (搜索) supply that may be impaired by disease, injury, or aging, promoting authentic nerve functioning. Unlike existing compensatory treatments, this approach acts as a restorative therapy by stimulating the cavernous nerves at a time when injury is predictable.
"The strength of this technology lies in its alignment with our understanding of erectile neurophysiology," explained Rodrigo Fraga, PhD, COO of Comphya (搜索) and co-author of the Nature review. "By stimulating the cavernous nerves at a time when injury is predictable, we may be able to promote neural rehabilitation and facilitate functional recovery rather than accepting postoperative erectile dysfunction (搜索) as inevitable."
Technology Overview
CaverSTIM (搜索) is the first implantable neurostimulator designed specifically to restore erectile function. The system consists of an implantable pulse generator (IPG) containing a rechargeable battery and electronics that generate electrostimulation signals. The IPG connects to an array of electrodes implanted in the pelvic cavity to activate nerves responsible for penile erection.
The device is implanted subcutaneously in the lower abdomen and operated remotely via external controllers. A clinician controller allows medical professionals to adjust system parameters for individual patients, while a programmed daily stimulation routine, generally imperceptible to patients, begins during the crucial nerve function recovery period.
Future Clinical Development
Building on these encouraging results, Comphya (搜索) announced plans to initiate larger controlled clinical trials following completion of the pilot studies. The expanded trials will further assess the safety, tolerability, and efficacy of CaverSTIM (搜索) in restoring erectile function post-prostatectomy.
The company is also exploring the technology's application for other neurogenic causes of erectile dysfunction (搜索), including spinal cord injury, potentially expanding the treatment's reach to additional patient populations with limited therapeutic options.